Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.69 |
| ▸ | MAPT | P10636 | 5/20 | 0.62 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.62 |
| ▸ | HPGD | P15428 | 4/20 | 0.62 |
| ▸ | LMNA | P02545 | 3/20 | 0.62 |
| ▸ | MAOB | P27338 | 2/20 | 0.62 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.62 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.59 |
| ▸ | MEN1 | O00255 | 4/20 | 0.59 |
| ▸ | GAA | P10253 | 1/20 | 0.59 |
| ▸ | ALOX12 | P18054 | 3/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.57 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | MAOA | P21397 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4345394 | 0.86 | MEN1 (0.74) | SMN1; SMN2MAPTHPGDLMNAMAOB | |
| SCHEMBL4350377 | 0.83 | CA12 (0.66) | MAPTKMT2AMEN1ALDH1A1ALOX15 | |
| SCHEMBL4359738 | 0.83 | KMT2A (0.58) | SMN1; SMN2MAPTNPSR1HPGDLMNA | |
| SCHEMBL4354009 | 0.82 | SMN1; SMN2 (0.60) | SMN1; SMN2MAPTNPSR1HPGDLMNA | |
| SCHEMBL4351089 | 0.81 | LMNA (0.64) | SMN1; SMN2MAPTNPSR1HPGDLMNA | |
| SCHEMBL5447928 | 0.80 | SMN1; SMN2 (0.68) | SMN1; SMN2MAPTNPSR1HPGDLMNA | |
| SCHEMBL4342059 | 0.79 | ALDH1A1 (0.69) | SMN1; SMN2MAPTNPSR1HPGDLMNA | |
| SCHEMBL3261173 | 0.79 | ALOX15 (0.56) | MAPTHPGDKMT2AMEN1ALOX12 | |
| SCHEMBL4349794 | 0.77 | MAPT (0.67) | SMN1; SMN2MAPTNPSR1HPGDLMNA | |
| SCHEMBL4346204 | 0.77 | SMN1; SMN2 (0.57) | SMN1; SMN2MAPTHPGDLMNAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110065760-A1 | COMPOUNDS FOR THE INHIBITION OF ROTAMASES AND USE THEREOF | JERINI AG (DE) | 2011-03-17 | — | — | US | claimed |
| CN-100546977-C | Suppress the new compound and the application thereof of rotamase | JERINI AG (DE) | 2009-10-07 | — | — | CN | claimed |
| EP-2100876-A2 | New compounds for the inhibition of rotamases and use thereof | Jerini AG (DE) | 2009-09-16 | — | — | EP | claimed |
| US-20070054904-A1 | Phenol derivatives and their use as rotamase inhibitors | JERINI AG (DE) | 2007-03-08 | — | — | US | claimed |
| CN-1701061-A | Novel compounds for inhibiting rotamase enzymes and uses thereof | JERINI AG (DE) | 2005-11-23 | — | — | CN | claimed |
| EP-2100876-A2 | New compounds for the inhibition of rotamases and use thereof | Jerini AG (DE) | 2009-09-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110065760-A1 | COMPOUNDS FOR THE INHIBITION OF ROTAMASES AND USE THEREOF | NR1I3, NR1D1, NR1D2 | SMN1; SMN2 1791/4885MAPT 4439/4885NPSR1 99/4885 |
| US-20070054904-A1 | Phenol derivatives and their use as rotamase inhibitors | NR1I3, NR1D1, NR1D2 | SMN1; SMN2 3250/4885MAPT 4184/4885NPSR1 240/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.